The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
The the US Food and Drug Administration (FDA) has approved the first medication to ... The agency said that along with the drug, a reduced-calorie diet and increased physical activity should ...
On Dec. 20, the FDA announced that the agency has approved Eli Lilly's ... in adults with obesity. The drug is to be paired with a reduced-calorie diet and increased physical activity, the FDA ...
It should be used with a reduced-calorie diet and ... the new FDA green light doesn’t expand the number of people who may be eligible for the drug, since the sleep apnea approval is specifically ...